Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 64.70 Bil Enterprise Value: 57.96 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 11:00PM GMT
Release Date Price: MXN751.98
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

All right. Let's go ahead and get started. Welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Malcolm Kuno, Priyanka Grover and [Marea Hall].

Our next presenting company is Ultragenyx, and presenting on behalf of the company, we have CEO, Emil Kakkis. Emil?

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director

Thank you. Good to see all of you today. It's been my 20th, so it's 42, but I'm -- my 20th here. So it's great to be here and give you an update on Ultragenyx. We have a big year ahead. 2024 is a big year, a lot of build up, putting us in good position, and we'll talk a little about that update today.

Forward-looking statement for all of you.

Now, I think if you look at what we've been doing in our 10th year from going public, we're just coming up to our 10th anniversary of going public, I think we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot